Identifying the clinical profile of breast cancer women harboring BRCA1 gene hypermethylation may help oncologists to select the subgroup of patients who may be candidates for BRCA1 methylation assessment, thus, possibly enlarging the cancer population who may benefit from new target-therapy agents. This evidence concerns the gene BRCA1 and cancer.